Cargando…

Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases

Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, aba...

Descripción completa

Detalles Bibliográficos
Autores principales: Richi, Patricia, Yuste, Jose, Navío, Teresa, González-Hombrado, Laura, Salido, Marina, Thuissard-Vasallo, Israel, Jiménez-Díaz, Ana, Llorente, Jesús, Cebrián, Laura, Lojo, Leticia, Steiner, Martina, Cobo, Tatiana, Martín, María Dolores, García-Castro, Marta, Castro, Patricia, Muñoz-Fernández, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997274/
https://www.ncbi.nlm.nih.gov/pubmed/33671007
http://dx.doi.org/10.3390/vaccines9030203
_version_ 1783670291612827648
author Richi, Patricia
Yuste, Jose
Navío, Teresa
González-Hombrado, Laura
Salido, Marina
Thuissard-Vasallo, Israel
Jiménez-Díaz, Ana
Llorente, Jesús
Cebrián, Laura
Lojo, Leticia
Steiner, Martina
Cobo, Tatiana
Martín, María Dolores
García-Castro, Marta
Castro, Patricia
Muñoz-Fernández, Santiago
author_facet Richi, Patricia
Yuste, Jose
Navío, Teresa
González-Hombrado, Laura
Salido, Marina
Thuissard-Vasallo, Israel
Jiménez-Díaz, Ana
Llorente, Jesús
Cebrián, Laura
Lojo, Leticia
Steiner, Martina
Cobo, Tatiana
Martín, María Dolores
García-Castro, Marta
Castro, Patricia
Muñoz-Fernández, Santiago
author_sort Richi, Patricia
collection PubMed
description Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol.
format Online
Article
Text
id pubmed-7997274
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79972742021-03-27 Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases Richi, Patricia Yuste, Jose Navío, Teresa González-Hombrado, Laura Salido, Marina Thuissard-Vasallo, Israel Jiménez-Díaz, Ana Llorente, Jesús Cebrián, Laura Lojo, Leticia Steiner, Martina Cobo, Tatiana Martín, María Dolores García-Castro, Marta Castro, Patricia Muñoz-Fernández, Santiago Vaccines (Basel) Article Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol. MDPI 2021-02-28 /pmc/articles/PMC7997274/ /pubmed/33671007 http://dx.doi.org/10.3390/vaccines9030203 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Richi, Patricia
Yuste, Jose
Navío, Teresa
González-Hombrado, Laura
Salido, Marina
Thuissard-Vasallo, Israel
Jiménez-Díaz, Ana
Llorente, Jesús
Cebrián, Laura
Lojo, Leticia
Steiner, Martina
Cobo, Tatiana
Martín, María Dolores
García-Castro, Marta
Castro, Patricia
Muñoz-Fernández, Santiago
Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
title Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
title_full Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
title_fullStr Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
title_full_unstemmed Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
title_short Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
title_sort impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997274/
https://www.ncbi.nlm.nih.gov/pubmed/33671007
http://dx.doi.org/10.3390/vaccines9030203
work_keys_str_mv AT richipatricia impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT yustejose impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT navioteresa impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT gonzalezhombradolaura impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT salidomarina impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT thuissardvasalloisrael impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT jimenezdiazana impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT llorentejesus impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT cebrianlaura impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT lojoleticia impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT steinermartina impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT cobotatiana impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT martinmariadolores impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT garciacastromarta impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT castropatricia impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases
AT munozfernandezsantiago impactofbiologicaltherapiesontheimmuneresponseafterpneumococcalvaccinationinpatientswithautoimmuneinflammatorydiseases